It has been proposed that genetic variants can affect the development and clinical course of cardiovascular disease (CVD) by a number of behavioral and biological pathways that are ultimately involved in CVD pathogenesis and precipitation of clinical CVD events. 1 These pathways may include an inclination toward increased hypothalamicpituitary-adrenal (HPA) axis activation in response to psychosocial stress, obesity, inflammation, and more severe addiction to tobacco. The gene that encodes brain-derived neurotrophic factor (BDNF) is a promising candidate to be associated with the development and course of CVD. BDNF protein is an important neurotrophin, regulating survival and growth of neurons and synapses, 2 and protecting against stress-induced neuronal damage. 3 The BDNF rs6265 G/A variant has been shown to be functional, changing a valine at position 66 of the BDNF protein to a methionine (Val66Met 4, 5 ) and has, therefore, received considerable attention with respect to the above risk factors.
A number of epidemiologic studies, for example, have found that Val carriers have higher body mass index (BMI) [6] [7] [8] [9] than Met carriers. In a study of the association between the Val66Met polymorphism and metabolic risk variables among patients with fibromyalgia syndrome, 10 the Val/Val genotype was associated with higher mean BMI and From the a high-sensitivity C-reactive protein (hsCRP) levels than did those carrying the Met genotype. Jiang et al 11 also reported that among patients with unstable angina pectoris, Val/Val genotype was associated with higher plasma hsCRP levels than Met carriers. In our previous work, 12 we found a consistent pattern in 2 independent samples that the depressive symptom levels as a function of chronic stress increased significantly more among persons with the Val/Val genotype than among Met carriers. We have also found that blood cortisol levels are higher in Val/Val females during a laboratory stress protocol of anger and sadness recall than in Met females in an experimental study. 13 The latter finding may be relevant to CVD in that chronically increased HPA axis function, indicated by elevated hair cortisol levels, also has been associated with increased risk of acute myocardial infarction (MI) in men.
14 Moreover, larger salivary cortisol responses to mental stress in men and women have been associated with increased levels of coronary artery calcification. 15 Studies also have shown a larger HPA axis and cardiovascular responses to acute psychosocial stress in Val/ Val males. 16, 17 The higher plasma hsCRP level is an independent predictor of cardiovascular events. 18, 19 Given the above, we hypothesized that the Val/Val genotype would be associated with increased severity of coronary artery disease (CAD) and incidence of CVD mortality and morbidity in a large sample of Caucasian patients, who have been evaluated in the cardiac catheterization laboratory at Duke University Hospital (Durham, NC).
Methods

Participants
The collection of data on CATHeterization GENetics (CATHGEN) participants has been described in detail elsewhere. [20] [21] [22] Briefly, CATHGEN study participants were recruited through the cardiac catheterization laboratories at Duke University Hospital (Durham, NC), with approval from the Duke Institutional Review Board, and all participants signed informed consent. Although the CATHGEN study comprises variety of ethnic groups, most participants are Caucasian (75.0%). To avoid the confounding effects of population stratification while maximizing our power to detect genetic associations, we chose to analyze the Caucasian participants only. In the present study, we included 5,510 Caucasian participants who had data on the variables interest and covariates.
Genotyping
Genomic DNA was extracted from frozen whole blood samples collected from the participants during cardiac catheterization. The BDNF Val66Met (rs6265) singlenucleotide polymorphism (SNP) was genotyped using the Taqman genotyping assay (Life Technologies, Grand Island, NY) and the Type-It Fast Probe PCR kit (Qiagen, Germantown, MD). For each 5 μL reaction, a solution containing 2 μL Type-It Fast Probe PCR Master Mix (Qiagen), 0.05 μL 80× Taqman assay (Life Technologies), and 0.5 μL Q-solution (Qiagen) was added to 3 ng of dried DNA template. The temperature program was 95°C for 5 minutes, then 50 cycles of 95°C for 15 seconds and 60°C for 30 seconds, run on the GeneAmp PCR system 9700 (Life Technologies). Fluorescence was read and analyzed on the ViiA 7 instrument (Life Technologies). Polymerase chain reactions were performed in 384-well format with 4 negative controls. The SNP genotype call rate was greater than 95%, and the genotype frequencies were in Hardy-Weinberg equilibrium (P = .866).
Disease severity: number of diseased vessels and left ventricular ejection fraction Severity of CAD was determined as an ordinal variable defined as the number of diseased vessels (NDV) with significant (≥75%) stenosis as determined by the interventional cardiologist performing the procedure. The greater the value of NDV (0-3), the more severe the CAD. Left ventricular ejection fraction (LVEF) is expressed as the percentage of blood pumped out of the left ventricle on systole. It was measured either during cardiac catheterization, or medical record review for an echocardiogram, nuclear study, or cardiac magnetic resonance imaging done within 1 year on either side of the catheterization.
Events
As part of the ongoing follow-up of the Duke Databank for Cardiovascular Diseases, CATHGEN participants are surveyed annually for CVD events and the participant list is compared with the National Death Index. The events were defined as death from any cause or MI (number of days from cardiac catheterization to the first subsequent MI had to be ≥7 to avoid any effects from cardiac catheterization), and they were followed up for up to 11.8 years with a median follow-up time of 5.9 years.
Risk factors
Body mass index and binary indicators of history of cigarette smoking, dyslipidemia, hypertension, and history of diabetes were all assessed at the time cardiac catheterization, that is, at the beginning of the study. No data were available to provide a measure of life stress or depression.
Statistical analyses
All analyses were performed using SAS version 9.4 (SAS Inc, Cary, NC). Patients who were homozygous for the Met allele were combined with the heterozygous individuals as the Met group to be compared with homozygous Val/Val patients. Demographic, risk factor, and disease severity variables were compared between Val66Met genotypes (Val/Val vs Met) using linear, binary logistic or ordinal logistic regression adjusting for age and sex, depending on the measurement characteristics of the outcome variable. Cox regression models were estimated using defined events as the response variable. Participants who were lost to follow-up or who had not experienced an event by the last date of follow-up were coded as censored. Our primary analysis was to test the Val66Met genotype association with death or MI using proportional hazards models, carried out in 3 incremental stages: model 1, adjusting for age and sex; model 2, adding adjustment for the risk factors of BMI, history of smoking, history of diabetes, history of dyslipidemia, and history of hypertension; and model 3, adding adjustment for the potential mediating mechanisms of LVEF and NDV. Proportional hazards assumption was met for all models. We also evaluated the association of Val66Met with NDV and LVEF using ordinal logistic regression model and linear regression, respectively. Using the SPOWER simulation algorithm available in the rms package in R, we estimated that we had 80% power at α = .05 to detect a hazard ratio (HR) of at least 1.30 favoring the Val/Val group compared with Met carriers.
Results
The clinical characteristics of the study sample are presented in Table I compared with the Met group (n = 529; 28.1%), but this difference was not statistically significant (P = .104).
The fitted survival curves for both genotypes are presented in Figure, quantified in the Cox regression model. Parallel to the raw event frequency counts, Val/Val homozygotes had the more rapid time-to-event rate. Table II displays the results of HRs in the age/sex only adjusted (model 1) and additional covariate-adjusted Cox regression models (model 2 and model 3). In the age/sex-only-adjusted Cox model (see Table II , model 1), Val/Val homozygotes were at higher risk than Met carriers for the clinical CVD events of all-cause death or MI (HR 1.12, 95% CI 1.01 to 1.24, P = .034). After adjusting for additional risk factors (model 2) including BMI, history of diabetes, history hypertension, history of dyslipidemia, and smoking history (see Table II , model 2), the increased risk for Val/Val still remained (HR 1.11, 95% CI 1.00 to 1.24, P = .04). However, after further adjusting for additional CAD severity indicated by NDV and/or LVEF, the effect of Val66Met on the clinical events was no longer significant (HR 1.08, 95% CI 0.97 to 1.20, P = .148). Additional analyses including one disease severity measure at a time both resulted in the effect of Val66Met being reduced and no longer statistically significant (for Vall66Met with NDV only: HR 1.09, 95% CI 0.98 to 1.21, P = .096; LVEF only: HR 1.10, 95% CI 0.99 to 1.22, P = .072). In terms of the effects of the covariates in the models, with the exception of history of hypertension and sex, all of the adjustment covariates were associated with CVD events in the fully adjusted (model 3, adjusted for risk factors, NDV, and LVEF) Cox regression model (see Table II , model 3). Older age, history of smoking, history of diabetes, and a higher number of coronary arteries were associated with increased rates of events, whereas higher BMI, higher LVEF, and history of dyslipidemia were associated with a lower risk of events.
The ordinal logistic regression model using Val66Met to predict NDV, adjusted only for age and sex, showed that the Val/Val participants had a greater risk for higher CAD severity (higher NDVs) than did Met participants (OR 1.17, 95% CI 1.06 to 1.30, P = .002). After adjusting for additional risk factors, the point estimate for Val66Met was slightly reduced, but remained significantly related to NDV (OR 1.15, 95% CI 1.04 to 1.28, P = .008,). The linear regression model of LVEF adjusted for age and sex also indicated that Val/Val homozygotes had a higher risk of higher CAD severity (lower LVEF) than did Met carriers (β = −0.72, 95% CI −1.42 to −0.02, P = .044). After adjusting for additional risk factors, the higher risk of LVEF for Val/Val remained statistically significant (β = −0.70, 95% CI −1.40 to −0.001, P = .0497). However, adjusting for both risk factors and NDV, the effect of Val66Met on LVEF became nonsignificant (β = −0.52, 95% CI −1.21 to −0.17, P = .142).
Discussion
The BDNF Val66Met polymorphism was associated with CAD severity and clinical CVD events over a median 5.9-year follow-up period in our clinical sample. Specifically, Val/Val homozygotes had more diseased vessels, lower LVEF, and a 12% higher hazard of clinical CVD events compared with Met carriers. Adjustment for demographics and conventional risk factors did not explain the association between the genetic variant and clinical events, ruling out confounding with these factors. However, adjustment for the 2 disease severity markers did reduce the gene-event association, whereas the variant was associated with both of the disease markers. Taken together, these observations suggest that one way the variant may be influencing event risk is by way of its impact on atherogenesis. As we have noted, our hypothesis that Val66Met would be related to cardiac clinical events was based on prior literature that showed associations between the variant and risk factors for CAD, including depressive symptoms, 12 and larger HPA axis reactivity. 13, 16, 17 The present finding lends further support to this proposition. These findings also are consistent with at least one study of Val66Met with respect to CAD, which found that the Val/ Val genotype, compared with Met carriers, was associated with a higher occurrence of unstable angina pectoris in the population of Han Chinese.
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The current findings may have important implications for the development of targeted preventive interventions and treatments. It has been shown, for example, that cognitive behavioral stress management training produces reduced anxiety and cortisol levels that are maintained over a 12-month follow-up period in women undergoing treatment of breast cancer 23 as well as reduced depression and blood pressure and heart rate both at rest and during acute mental stress in men recovering from coronary artery bypass surgery. 24 Two randomized controlled trials of cognitive behavioral stress management training delivered in small groups of CHD patients found that those receiving CBMS training had reduced mortality and recurrent clinical events. 25, 26 A clinical trial of such cognitive behavioral stress management training in CHD patients homozygous for the BDNF Val allele could, for example, result in improved prognosis.
There are several limitations to the present study that should be noted. Indices of HPA axis function were not available in the sample, making it impossible to directly test the role of increased HPA axis function as a mechanism mediating adverse outcomes among those with the Val/Val genotype. The absence of adequate measures of depressive symptom levels in the patients makes it impossible to test the association of depression with HPA axis function and/or clinical events. Other factors such as physical exercise, life styles, and gene-gene interaction could also impact the outcomes. Future studies in African Americans need to be done to see if Val/Val associations with disease severity and prognosis are similar to those found in Caucasian CHD patients. Although compelling evidence indicates that this functional BDNF Val66Met coding variant should be considered a prime candidate influencing the development and the course of CHD, further investigation of the genetic sequence in the remainder of the gene and in the nearby regions should be performed to determine whether it is the causal variant creating that CHD risk and whether better genetic markers of that risk exist. Despite these limitations, the consistency of the association of the Val66Met Val/Val genotype with more severe documented coronary atherosclerosis, reduced LVEF, and increased CHD event rates makes a strong case that the Val66Met polymorphism deserves continuing attention in the search for genetic variants that potentiate effects of environmental stress on the development and course of CHD. Further replication and studies on the underlying mechanisms should be done-for instance, the effects of genetic variants might be via methylation profiling and/or gene expression on the endophenotypes in the development of CVD.
In conclusion, we found that a functional BDNF SNP, Val66Met, that has been previously associated with increased cortisol response to stress, depression, and metabolic traits linked to CVD was associated with increased CAD severity and incidence of death or MI, independent of traditional CHD risk factors in a large clinical sample of Caucasian patients. If these findings are replicated in further research, behavioral and pharmacologic interventions to reduce HPA axis reactivity and depression in Val/Val carriers could be potentially used as a means of improving CVD-related prognosis in patients, and ultimately in primary prevention.
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